This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Hutchison MediPharma Limited
Drug Names(s): HMPL-013
Description: Fruquintinib is a selective VEGFR inhibitor.
Hutchison MediPharma and Lilly
In October 2013, Hutchison MediPharma (HMP) announced that entered into a licensing, co-development, and commercialisation agreement in China with Eli Lilly (Lilly) for Fruquintinib (HMPL-013) for the potential treatment of various types of solid tumours. Under the terms of the agreement, the costs of future development of Fruquintinib in China, to be carried out by HMP, will be shared between HMP and Lilly. HMP will potentially receive a series of payments of up to US$86.5 million, including upfront payments and development and regulatory approval milestones. Should Fruquintinib be successfully commercialised in China, HMP would receive tiered royalties starting in the mid-teens percentage of net sales. Additional terms of the agreement were not disclosed.
Partners: Eli Lilly & Company
Additional information available to subscribers only: